Cellevate AB
Linda Dexlin Mellby is currently the Vice President of Research And Development at Cellevate AB since November 2022. Prior to this role, Linda held the same position at Immunovia AB from September 2013 to November 2022, where Linda also served as Laboratory Manager. Linda started their career as a Researcher at Immunotechnology from September 2011 to September 2013. Linda holds a PhD in Immunotechnology from Lund University, where Linda also earned a Master of Science in Chemical Engineering from The Faculty of Engineering, LTH. Linda completed their secondary education at Vasaskolan, Gävle.
Cellevate AB
Cellevate develops and markets products based on a proprietary nanofiber-based platform - the Cellevat3d™ - with the potential to revolutionize upstream bioprocessing from R&D to commercial manufacturing. Our latest product line in development – Cellevat3d™ carriers – with a commercial launch planned for 2024, provides extracellular-like environments with exceptional surface areas for adherent cell cultures. Initial results show tremendous potential to increase yields, minimize risk and reduce costs in development and manufacturing. We offer a range of products based on our versatile and easily functionalized platform for several applications, including next generation cell- and gene therapies. For more information, please visit www.cellevate.com